logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Metastatic Nonsmall Cell Lung Cancer

    FiltersReset Filters
    11 results

    • braftovi

      (Encorafenib)
      Array BioPharma Inc.
      Usage: BRAFTOVI is indicated for the treatment of unresectable or metastatic melanoma, metastatic colorectal cancer, and metastatic non-small cell lung cancer, all positive for BRAF V600E or V600K mutations. These treatments require combination therapies and FDA-approved testing for mutation detection. Not for wild-type BRAF cancers.

    • keytruda

      (pembrolizumab)
      Merck Sharp & Dohme LLC
      Usage: KEYTRUDA® is indicated for various cancers, including unresectable or metastatic melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and classical Hodgkin lymphoma, among others. It is utilized in different settings, such as first-line treatment, adjuvant therapy, and for those with advanced or refractory disease.

    • lorbrena

      (lorlatinib)
      Pfizer Laboratories Div Pfizer Inc
      Usage: LORBRENA® is indicated for treating adult patients with metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive, confirmed by an FDA-approved test.

    • mektovi

      (BINIMETINIB)
      Array BioPharma Inc.
      Usage: MEKTOVI is indicated, in combination with encorafenib, for treating unresectable or metastatic melanoma and metastatic non-small cell lung cancer (NSCLC) in adult patients with BRAF V600E or V600K mutations, as identified by FDA-approved testing.

    • rybrevant

      (Amivantamab)
      Janssen Biotech, Inc.
      Usage: RYBREVANT is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations, both as a first-line treatment and for those previously treated, in combination with approved therapies or as a single agent.

    • tabrecta

      (capmatinib)
      Novartis Pharmaceuticals Corporation
      Usage: TABRECTA is indicated for adult patients with metastatic non-small cell lung cancer (NSCLC) characterized by a mutation causing MET exon 14 skipping, as determined by an FDA-approved test.

    • tecentriq

      (atezolizumab)
      Genentech, Inc.
      Usage: TECENTRIQ is indicated for various cancers: as adjuvant treatment and first-line therapy for non-small cell lung cancer (NSCLC); for extensive-stage small cell lung cancer (ES-SCLC); for unresectable or metastatic hepatocellular carcinoma (HCC); and for melanoma with BRAF V600 mutation. It also treats unresectable alveolar soft part sarcoma.

    • tepmetko

      (Tepotinib Hydrochloride)
      EMD Serono, Inc.
      Usage: TEPMETKO is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) that has mesenchymal-epithelial transition (MET) exon 14 skipping alterations.

    • vizimpro

      (dacomitinib)
      Pfizer Laboratories Div Pfizer Inc
      Usage: VIZIMPRO is indicated for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients with specific EGFR mutations (exon 19 deletion or exon 21 L858R), as identified by an FDA-approved test.

    • xalkori

      (CRIZOTINIB)
      Pfizer Laboratories Div Pfizer Inc
      Usage: XALKORI is indicated for adults and pediatric patients aged 1 year and older with metastatic non-small cell lung cancer (NSCLC) that is ALK or ROS1-positive, as well as relapsed or refractory systemic ALK-positive anaplastic large cell lymphoma (ALCL), and unresectable, recurrent, or refractory ALK-positive inflammatory myofibroblastic tumors.